NasdaqCM - Delayed Quote • USD
OncoCyte Corporation (OCX)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.67 | -0.6 | -2.39 | -1.98 |
| Low Estimate | -0.74 | -0.72 | -2.84 | -2.61 |
| High Estimate | -0.57 | -0.37 | -1.57 | -0.89 |
| Year Ago EPS | 0.4 | -1.07 | -3.75 | -2.39 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 350k | 400k | 1.83M | 5.9M |
| Low Estimate | 300k | 300k | 1.1M | 2.61M |
| High Estimate | 400k | 500k | 2.6M | 8.5M |
| Year Ago Sales | 297k | 463k | 1.5M | 1.83M |
| Sales Growth (year/est) | 17.80% | -13.60% | 21.80% | 222.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.84 | -1.3 | -1.01 | -1.14 |
| EPS Actual | 0.4 | -1.07 | -0.81 | -2.12 |
| Difference | 2.24 | 0.23 | 0.2 | -0.98 |
| Surprise % | 121.70% | 17.70% | 19.80% | -86.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.67 | -0.6 | -2.39 | -1.98 |
| 7 Days Ago | -0.75 | -0.65 | -2.95 | -2.52 |
| 30 Days Ago | -0.76 | -0.61 | -3.01 | -2.43 |
| 60 Days Ago | -0.76 | -0.61 | -3.01 | -2.43 |
| 90 Days Ago | -0.76 | -0.61 | -3.01 | -2.43 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | OCX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -267.50% | -- | -- | 2.60% |
| Next Qtr. | 43.90% | -- | -- | 13.40% |
| Current Year | 36.30% | -- | -- | 5.20% |
| Next Year | 17.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Needham: Buy to Buy | 4/24/2024 |
| Reiterates | Stephens & Co.: Equal-Weight to Equal-Weight | 4/17/2024 |
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 4/15/2024 |
| Maintains | Piper Sandler: Neutral to Neutral | 11/13/2023 |
| Maintains | Needham: Buy to Buy | 11/9/2023 |
| Maintains | Benchmark: Speculative Buy to Speculative Buy | 8/24/2023 |
Related Tickers
GENI.L GENinCode Plc
7.45
-3.94%
VNRX VolitionRx Limited
0.8902
+11.27%
STRR Star Equity Holdings, Inc.
0.8781
+1.51%
CDNA CareDx, Inc
7.56
-5.26%
LMDXF LumiraDx Limited
0.0154
-9.65%
CSTL Castle Biosciences, Inc.
19.51
-1.76%
BNR Burning Rock Biotech Limited
0.8500
+3.56%
CNTG Centogene N.V.
0.4799
+4.10%
NEOG Neogen Corporation
11.96
-3.31%
NDRA ENDRA Life Sciences Inc.
0.2425
-6.69%